Latest news with #inflammatory
CBS News
4 days ago
- Health
- CBS News
2 years after brain swelling scare, Shorewood toddler is back to her spunky self
Four-year-old Sydney Marcus is a fast-moving, spunky kiddo. "[She was] just very chatty, mobile, running around, learning, just like a little sponge," Sydney Marcus' mom, Britta Marcus, said. But one night two years ago, Sydney Marcus flipped like a light switch. "It was kind of like a one-in-a-million fluke, essentially and her body reacted to it and started attacking itself," Britta Marcus said. She says her toddler went to bed with a run-of-the-mill fever, cold and runny nose — and didn't wake up. "It was just a overnight light switch of where she went from like a healthy, normal kid, and woke up unresponsive," Britta Marcus said. Sydney Marcus was rushed to the hospital where doctors determined a rare, inflammatory condition called cerebellitis was causing swelling, fluid and pressure build-up in her brain. The cause was a combination of common cold viruses. "It's extremely rare. I mean, there's there some case reports that we'll talk about it being one in 500,000 and even one in a million, if million, it's extremely rare," Sydney Marcus' neurosurgeon at Children's Minnesota, Dr. Meysam Kebriaei, said. Sydney Marcus underwent two emergency surgeries at Children's Minnesota. "They removed a small piece of her skull and put a drain into her fluid space to try to relieve the pressure that way," Kebriaei said. The next challenge came post-surgery: rehab. She had to relearn everything — from walking to talking to swallowing her food. "It was literally starting over, like, with a newborn," Sydney Marcus' dad, Ross Marcus, said. "From a neurosurgical perspective, she's 100% and, like, that's, that's the emotional piece, right? Like, we're incredibly lucky to be in this situation." Thanks to physical therapy and rehab, Sydney Marcus is now returning to her spunky self. "I think she's going to have a bright future," Kebriaei said. These days, Sydney Marcus is busy blowing bubbles and chasing her two older sisters. "We were just could not have been more impressed, truly, with the care, the diversity of thought and the consistency of like, their presence and their support of our family," Ross Marcus said. The Marcus family says it's that support that saved their daughter's life. "Giving people hope is something you don't have the opportunity to do a lot, and in those darkest moments, is what really pushes you through and really gets you through and helps you fight for your child, right? And if we can provide that, I mean, we will do it all day long," Ross Marcus said. Doctors say cerebellitis is rare and even more rare in children. Doctors reiterate a common cold is typically nothing to worry about.
CNA
7 days ago
- Business
- CNA
Novartis to pay Matchpoint up to $1 billion to develop anti-inflammatory therapies
Swiss drugmaker Novartis will pay up to $1 billion to U.S. biotech Matchpoint Therapeutics to develop oral drugs for several inflammatory diseases. Matchpoint said on Thursday it will use its technology to develop drugs that block the activity of a specific protein, helping to lower the production of inflammation-causing signals. The company will lead the research and drug development process, using the funding from Novartis. If Novartis exercises its option to exclusively license the program, the drugmaker will have global rights to develop and commercialize all products resulting from the collaboration. Matchpoint said it will receive up to $60 million in upfront payment and research funding, with up to $1 billion in total potential payments, including option exercise fee, and development and commercial milestones.
Reuters
7 days ago
- Business
- Reuters
Novartis to pay Matchpoint up to $1 billion to develop anti-inflammatory therapies
July 24 (Reuters) - Swiss drugmaker Novartis (NOVN.S), opens new tab will pay up to $1 billion to U.S. biotech Matchpoint Therapeutics to develop oral drugs for several inflammatory diseases. Matchpoint said on Thursday it will use its technology to develop drugs that block the activity of a specific protein, helping to lower the production of inflammation-causing signals. The company will lead the research and drug development process, using the funding from Novartis. If Novartis exercises its option to exclusively license the program, the drugmaker will have global rights to develop and commercialize all products resulting from the collaboration. Matchpoint said it will receive up to $60 million in upfront payment and research funding, with up to $1 billion in total potential payments, including option exercise fee, and development and commercial milestones.
Globe and Mail
22-07-2025
- Business
- Globe and Mail
Palisade Bio Participates in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference
– Video webcast now available on-demand Carlsbad, CA, July 22, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) ('Palisade', 'Palisade Bio', or the 'Company'), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced JD Finley Chief Executive Officer of Palisade Bio, participated in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference. As part of the event, Mr. Finley dove deeper into his dedication to the Company, how he got to where he is today and provided insight into why he is so passionate about the Company's programs in development. The on-demand video webcast is now available on as well as the Events page under the Investors section of the Company's website ( About Palisade Bio Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to
Yahoo
22-07-2025
- Business
- Yahoo
Palisade Bio Participates in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference
– Video webcast now available on-demand Carlsbad, CA, July 22, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) ('Palisade', 'Palisade Bio', or the 'Company'), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced JD Finley Chief Executive Officer of Palisade Bio, participated in the Virtual Investor 'What's Your Story' Summer Spotlight On-Demand Conference. As part of the event, Mr. Finley dove deeper into his dedication to the Company, how he got to where he is today and provided insight into why he is so passionate about the Company's programs in development. The on-demand video webcast is now available on as well as the Events page under the Investors section of the Company's website ( About Palisade Bio Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to Investor Relations Contact JTC Team, LLCJenene Thomas908-824-0775PALI@ while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
